Version 1.0 — Published October 2026
Quick Answer
Ten drug-drug interactions dominate INI-CET and NEET PG pharmacology — warfarin plus CYP2C9 inhibitors, MAOI plus SSRI (serotonin syndrome), methotrexate plus NSAID, macrolide plus statin (rhabdomyolysis), grapefruit plus CCB, rifampicin plus OCP, carbamazepine plus valproate, SSRI plus NSAID (GI bleed), cisapride plus azole (torsades), and ACE-I plus K-sparer plus NSAID (AKI). Master the mechanism, time to onset, and specific antidote for each — three to four questions in every INI-CET paper hinge on exactly these pairings.
Why This Matters for NEET PG & INI-CET
Pharmacology drug interactions sit at the intersection of three high-stakes NBEMS blueprints — mechanism (basic pharmacology), clinical correlate (medicine) and management (therapeutics). INI-CET's 200 MCQ, 180 min, +1/-1/3 paper will typically carry three to six drug-interaction stems — one classic (warfarin or OCP), one toxidrome (serotonin syndrome or rhabdomyolysis), one QT or arrhythmia stem (azole-cisapride, macrolide-amiodarone), and one subtle inducer or inhibitor pairing in a transplant or TB patient. NEET PG 2026, now a 180 MCQ, 720 marks, +4/-1, 210 min, 5-section paper, carries two to four interaction questions.
The reason these questions recur is simple — real inpatient medicine in India turns on them. A rural MO who misses warfarin-metronidazole produces an INR of 9 and a GI bleed. A psychiatry resident who switches fluoxetine to a MAOI without a 5-week washout produces a serotonin crisis. An orthopaedic surgeon who co-prescribes diclofenac with weekly methotrexate for RA produces pancytopenia. The question stems you will see on exam day are the audit trail of real adverse events, and the examiners pick the pairings that have the clearest mechanism and the cleanest management.
Beyond board exams, these ten interactions remain the top-cited drug errors in the WHO Patient Safety database and in India's Pharmacovigilance Programme reports. Learning them cold is the single highest-return hour of pharmacology revision in the last month before INI-CET.
1. Warfarin + CYP2C9 Inhibitors
Warfarin is a racemic mix of R and S enantiomers. The S enantiomer is 5 times more potent and is cleared via CYP2C9. Inhibitors of CYP2C9 raise S-warfarin levels, elevate INR, and precipitate bleeding within 3-7 days.
| Inhibitor | Mechanism | Peak INR rise | INR check |
|---|
| Amiodarone | CYP2C9 + CYP3A4 inhibitor | +30-50% | Weekly for 4 weeks |
| Metronidazole | CYP2C9 inhibitor | +40-60% | Day 3-5 |
| Fluconazole | CYP2C9 + CYP3A4 inhibitor | +50-80% | Day 2-4 |
| SMX-TMP | CYP2C9 inhibitor + protein displacement | +40-70% | Day 3-7 |
| Ciprofloxacin | CYP1A2 + CYP3A4 inhibitor | +20-30% | Day 3-5 |
Clinical rule: reduce warfarin dose by 30-50 percent at initiation of the inhibitor and check INR within 72 hours. Permanent reduction is needed only for chronic agents such as amiodarone.
MCQ 1. A 68-year-old woman on stable warfarin (INR 2.4) is started on co-trimoxazole for UTI. Three days later INR is 7.2 with no bleeding. Best next step?
A. IV vitamin K 10 mg
B. 4-factor PCC
C. Hold warfarin, recheck INR in 24 hours (correct)
D. Fresh frozen plasma
Rationale: INR less than 10 without bleeding = hold warfarin, no routine vitamin K per ACCP 2012.
2. MAOI + SSRI (Serotonin Syndrome)
Serotonin syndrome arises when two serotonergic agents stack. Classic pairs: MAOI (phenelzine, tranylcypromine, selegiline, linezolid) plus SSRI, SNRI, tramadol, meperidine, triptan, dextromethorphan, St John's wort, MDMA, cocaine.
Hunter criteria — one of:
- Spontaneous clonus
- Inducible clonus + agitation or diaphoresis
- Ocular clonus + agitation or diaphoresis
- Tremor + hyperreflexia
- Hypertonia + temperature greater than 38 degrees + clonus
Lower-limb clonus is characteristically more marked than upper-limb — a repeatedly tested exam point.
Management:
- Stop all serotonergic drugs.
- IV fluids, external cooling, benzodiazepine (diazepam 5-10 mg IV) for agitation and myoclonus.
- Cyproheptadine 12 mg PO loading then 2 mg every 2 hours — specific 5HT2A antagonist antidote.
- For temperature greater than 41 degrees: sedate, paralyse with vecuronium (never succinylcholine), intubate, actively cool.
Washout: 2 weeks between MAOI and SSRI; 5 weeks after fluoxetine stop (long half-life of norfluoxetine metabolite).
3. Methotrexate + NSAID (Renal Toxicity)
MTX is cleared by renal tubular secretion via OAT1/3. NSAIDs stack three hits — protein displacement, OAT competition, and prostaglandin-mediated afferent arteriolar vasoconstriction cutting GFR.
| MTX dose | Context | Risk of co-prescription |
|---|
| 7.5-25 mg weekly | RA, psoriasis | Moderate — hold NSAID on MTX day |
| 1-12 g per sq m | Oncology (osteosarcoma, lymphoma) | Life-threatening — strict avoidance |
Toxicity rescue:
- Calcium leucovorin 15 mg every 6 hours IV
- Hydration + urinary alkalinisation (sodium bicarbonate, urine pH greater than 7.5)
- Glucarpidase for MTX greater than 1 micromolar at 42 hours
Also contraindicated with MTX: trimethoprim-sulphamethoxazole (dihydrofolate reductase stacking), probenecid (OAT competition), PPIs (reduced MTX clearance).
4. Macrolide + Statin (Rhabdomyolysis)
Clarithromycin and erythromycin are strong CYP3A4 inhibitors. Simvastatin, lovastatin and atorvastatin are CYP3A4 substrates. Co-prescription raises statin AUC 5-10 fold, precipitating myopathy and rhabdomyolysis within days to weeks.
Safe pairings:
- Azithromycin (minimal CYP3A4 activity) + any statin
- Any macrolide + pravastatin or rosuvastatin (not CYP3A4 substrates)
- Any macrolide + pitavastatin (CYP2C9, minimal 3A4)
Red flag triad: macrolide + statin + fibrate (gemfibrozil) = acute rhabdomyolysis within 48 hours. CK greater than 10 times upper limit, AKI, dark urine, muscle pain.
5. Grapefruit Juice + CCB (and Many Others)
Grapefruit juice contains furanocoumarins (bergamottin, 6,7-dihydroxybergamottin) that mechanism-irreversibly inhibit intestinal CYP3A4. Effect persists 24-72 hours after a single glass.
Grossly elevated by grapefruit:
- Felodipine, nifedipine, amlodipine (CCBs — hypotension)
- Simvastatin, lovastatin, atorvastatin (rhabdomyolysis)
- Cyclosporine, tacrolimus (nephrotoxicity)
- Amiodarone, dronedarone (QT prolongation)
- Buspirone, triazolam, midazolam oral (sedation)
- Carbamazepine (ataxia, diplopia)
Not affected: pravastatin, rosuvastatin, diltiazem (less CYP3A4 dependent at intestinal level).
6. Rifampicin + OCP (Contraceptive Failure)
Rifampicin is the strongest clinical CYP3A4 and PGP inducer. Ethinylestradiol clearance roughly doubles within 1-2 weeks and persists 2-4 weeks after rifampicin stop.
Also induced by rifampicin:
- Warfarin (sub-therapeutic INR)
- Cyclosporine, tacrolimus (graft rejection)
- Phenytoin (seizures)
- HIV protease inhibitors (viraemia rebound)
- Ketoconazole, itraconazole (treatment failure)
- Sulphonylureas, methadone, levothyroxine
Alternative inducers (lower potency): phenytoin, carbamazepine, phenobarbital, St John's wort.
OCP counselling in a TB patient: use condoms or copper IUD throughout anti-TB therapy and for 4 weeks after. DMPA injection remains effective. Double-dose levonorgestrel emergency contraception.
7. Carbamazepine + Valproate
| Direction | Mechanism | Clinical effect |
|---|
| CBZ to VPA | CBZ induces VPA glucuronidation and beta-oxidation | VPA levels drop 20-30% |
| VPA to CBZ | VPA inhibits CBZ-epoxide hydrolase | CBZ-10,11-epoxide (toxic metabolite) rises 2-fold; drowsiness, diplopia, ataxia even at therapeutic CBZ level |
Classic exam stem: a child on CBZ monotherapy, controlled, is started on valproate for breakthrough myoclonic jerks and develops drowsiness and diplopia despite a therapeutic CBZ level of 8 micrograms/mL. Explanation: raised CBZ-epoxide not reflected in parent-drug assay.
Also VPA interactions worth memorising:
- VPA + lamotrigine = raised lamotrigine (titrate slowly to avoid Stevens-Johnson)
- VPA + aspirin = displaced VPA (toxicity)
- VPA + meropenem = dramatic VPA drop (seizure recurrence)
8. SSRI + NSAID (GI Bleed)
Platelets store serotonin passively from plasma — they lack the ability to synthesise it. SSRIs block the serotonin transporter on platelets, depleting granule content and impairing primary haemostasis. NSAIDs independently damage gastric mucosa by blocking COX-1-mediated prostaglandin production.
| Combination | Relative risk of upper GI bleed |
|---|
| NSAID alone | 3-4 fold |
| SSRI alone | 1.5-2 fold |
| SSRI + NSAID | 4-6 fold |
| SSRI + NSAID + warfarin | 10-15 fold |
Add a PPI if SSRI + NSAID is unavoidable, especially in patients greater than 65 years or with a prior ulcer. Consider SNRI switch (venlafaxine, duloxetine) — same mechanism, same risk. Mirtazapine and bupropion are safer alternatives.
9. Cisapride + Azoles (Torsades de Pointes)
Cisapride is a prokinetic 5HT4 agonist that was withdrawn in most markets in 2000 after causing QT prolongation and torsades. Mechanism: cisapride blocks the IKr potassium channel; CYP3A4 inhibitors (azoles, macrolides, grapefruit, HIV protease inhibitors) raise cisapride plasma levels into the arrhythmogenic range.
Still-exam-relevant QT prolonging combinations:
- Amiodarone + macrolide
- Methadone + fluoroquinolone
- Haloperidol + ondansetron
- Fluconazole + domperidone (the clinical heir of cisapride)
- Quinolone + sotalol
Any patient on two or more QT-prolonging agents needs a 12-lead ECG; QTc greater than 500 ms or an increase greater than 60 ms from baseline is the threshold to stop.
10. ACE-I + K-sparing Diuretic + NSAID ("Triple Whammy")
Each drug alone drops GFR modestly. Combined, they produce acute kidney injury and hyperkalaemia in elderly or volume-depleted patients within days.
- ACE-I/ARB: blocks angiotensin II-driven efferent arteriolar constriction. GFR falls.
- NSAID: blocks prostaglandin-driven afferent arteriolar dilation. GFR falls.
- K-sparer (spironolactone, eplerenone, amiloride, triamterene): blocks distal potassium secretion. K+ rises.
- Add dehydration (diarrhoea, vomiting, hot weather, diuretic): AKI accelerates.
Exam stem: a 78-year-old on ramipril, spironolactone and ibuprofen for arthritis presents after 2 days of gastroenteritis with creatinine 3.4 and K+ 6.8. Diagnosis: triple-whammy AKI with hyperkalaemia. Management: stop all three, IV fluids, calcium gluconate, insulin-dextrose, nebulised salbutamol, dialysis if indicated.
High-Yield One-Liners
- Warfarin plus metronidazole or fluconazole raises INR within 3-7 days — reduce warfarin by 30-50 percent.
- Hold warfarin for INR less than 10 without bleeding; do not routinely give vitamin K.
- Serotonin syndrome: lower-limb clonus greater than upper-limb; antidote cyproheptadine 12 mg PO.
- MAOI-SSRI washout: 2 weeks, except after fluoxetine (5 weeks for norfluoxetine).
- Methotrexate-NSAID: lethal in high-dose oncology MTX; manageable with hold-and-watch in RA.
- MTX rescue: calcium leucovorin, urinary alkalinisation above pH 7.5, glucarpidase if level greater than 1 micromolar at 42 hours.
- Macrolide plus statin: rhabdomyolysis within days — switch to pravastatin or rosuvastatin.
- Azithromycin plus any statin is safe; grapefruit plus simvastatin is not.
- Grapefruit CYP3A4 inhibition persists 24-72 hours after one glass.
- Rifampicin cuts OCP, warfarin, cyclosporine, protease inhibitor levels by 50-80 percent for 2-4 weeks after stopping.
- Valproate raises CBZ-epoxide, not parent CBZ — ataxia at therapeutic levels is a classic trap.
- SSRI plus NSAID plus warfarin raises GI bleed risk 10-15 fold.
- Mirtazapine and bupropion do not deplete platelet serotonin — safer with NSAID.
- QT drug stack = ECG mandatory, QTc greater than 500 ms stop.
- Triple whammy (ACE-I + K-sparer + NSAID) kills elderly kidneys in days.
Common Mistakes
- Giving IV vitamin K 10 mg for INR 6 with no bleeding — this is the wrong answer. ACCP 2012 and 2026 guidelines are clear: hold warfarin, do not routinely give vitamin K unless INR greater than 10 or bleeding.
- Confusing serotonin syndrome with NMS — NMS has lead-pipe rigidity, bradykinesia, hyporeflexia. Serotonin syndrome has clonus, hyperreflexia, lower-limb worse than upper-limb.
- Using succinylcholine in serotonin syndrome or NMS — worsens hyperkalaemia and rhabdomyolysis. Use rocuronium or vecuronium.
- Thinking rifabutin and rifampicin are interchangeable — rifabutin is a weaker CYP3A4 inducer and is the correct choice in HIV-TB co-therapy with protease inhibitors.
- Omitting folic acid in low-dose MTX patients — 5 mg weekly (not daily, not on MTX day) halves toxicity without reducing efficacy.
Related Topics on NEETPGAI
Practice This on NEETPGAI
Three to six INI-CET pharmacology questions every year test exactly these ten interactions. NEETPGAI's Pharmacology bank carries over 2,400 MCQs tagged by interaction class with mechanism-anchored explanations and AI Deep-Dive discussion for every stem. Start free — the full 28,000-plus MCQ bank, real previous-year questions, mock tests and analytics are open to every registered user. Sign up free and run a 20-question Pharmacology drug-interactions block tonight.
